8-K: DBV Technologies Board Member Resigns

Daniel Soland has resigned from DBV Technologies' Board of Directors and Compensation Committee, effective immediately.

Summary

• Daniel Soland notified DBV Technologies S.A.'s Board of Directors of his resignation from the Board and its Compensation Committee, effective September 18, 2025.
• His resignation was not the result of any dispute or disagreement with the Company or the Board.
• The Board of Directors will continue to operate with its 9 remaining members.
• The Nomination and Governance Committee will evaluate the appropriate timing and process for the provisional appointment of a new member to fill Mr. Soland's vacancy, subject to shareholder ratification at the next Annual General Meeting.
• DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions, primarily through its VIASKIN Peanut patch technology.

Sentiment

Score: 5

Explanation: The filing reports a routine board member resignation that is explicitly stated not to be due to any dispute or disagreement, indicating a neutral event without immediate positive or negative implications for the company's operations or financial health.

Positives

• Daniel Soland's resignation was explicitly stated not to be the result of any dispute or disagreement with the Company or the Board, indicating a smooth transition.
• The Board of Directors will continue to operate with 9 remaining members, ensuring continuity in governance.

Future Outlook

The Board's Nomination and Governance Committee will evaluate the appropriate timing and process for the provisional appointment of a new member to fill the vacancy, with ratification expected at the next Annual General Meeting. Daniel Soland expressed optimism for the Company's continued advancement of the VIASKIN Peanut patch.

Management Comments

• Michel de Rosen, Chairman of the Board, stated: "On behalf of the Board, DBV's management team and shareholders, I thank Daniel for his commitment to the Company. Since joining the Board in 2015, Daniel's experience, insights and expertise have been invaluable to the Board and its Compensation Committee. We wish him continued success in his future endeavors."
• Daniel Soland commented: "It has been a pleasure to serve on the Board and work with the DBV management team. I look forward to watching the Company continue to advance the VIASKIN Peanut patch and potentially bring a much needed treatment option to peanut allergic children and their families if approved."

Industry Context

DBV Technologies operates in the clinical-stage biopharmaceutical industry, specifically targeting food allergies, an area with significant unmet medical need. The company's focus on epicutaneous immunotherapy (EPIT) via its VIASKIN patch technology represents an innovative approach within this therapeutic space.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as the resignation was not due to disputes and the board remains functional with plans to fill the vacancy.
• Management: The management team expressed gratitude for Mr. Soland's contributions, suggesting a collegial departure.

Next Steps

• The Nomination and Governance Committee will evaluate the appropriate timing and process for the provisional appointment of a new Board member.
• The provisional appointment of a new Board member will be subject to ratification by the Company's shareholders at the next Annual General Meeting.

Key Dates

Keywords

DBV Technologies, DBVT, Board of Directors, Resignation, Biopharmaceutical, Food Allergies, VIASKIN Peanut, Clinical-stage